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INTRODUCTION 
 Rheumatic heart disease is a heart disease of global importance. Around 15.6 
million to 19.0 million people with Rheumatic heart disease live in middle and low 
social economic group.1,2  
          Patients with Rheumatic heart disease account for 1% to 5% of mortality all around 
the world.  India's contribution to global burden of Rheumatic heart disease is around 
20% to 50%.3,4 
 Rheumatic heart disease is post infection auto immune disease. Chronic 
Inflammation of myocardium leads to the damage of the heart valves. Mitral valve is 
affected most commonly followed by aortic valve. Least affected valves are tricuspid 
and pulmonary valves.5 
               Rheumatic heart disease patients require surgical interventions mainly to 
prevent them for complications like heart failure, pulmonary arterial hypertension 
and atrial fibrillation.6,7 
 Occurrence of thromboembolic events are increased in patients with 
mechanical valves therefore these patients should be treated with oral anti-coagulant 
of vitamin K antagonists. Acenocoumarol  is used widely in Europe and South 
America.8,9 Acenocoumarol  is 4-hydroxyl coumarin derivative most commonly used 
oral anti-coagulation is Acenocoumarol . It is short acting and has half-life of 
11hours.10 
 Acenocoumarol  has a narrow therapeutic index and relationship between dose 
and response is un-predictable. It is difficult to predict daily maintained dose of 
acenocoumarol  which the range from 1 mg to 56 mg. This wide variation is dose 
requirement is influenced by pharmacokinetic and pharamacodynamic aspects which 
in turn determined by genetic and environment factors. 
Because of large inter individual variation and response to acenocoumarol , this 
demands repeated and frequent monitoring of the international normalized ratio. The 
international normalized ratio of the prothrombin time is the important tool which is 
the standard laboratory investigation used to estimate the degree of anticoagulation 
and to access the need for dose regulation.11 
 The major side effects of oral anticoagulation is complications due to bleeding 
even when INR values are within the therapeutic range.12A meta-analysis was done 
for warfarin, acenocoumarol  and phenprocoumon showed that therapeutic drug 
monitoring of oral anticoagulants will ensures an optimal net benefit for the patients. 
Therapeutic drug monitoring is essential to first estimate the drug level is plasma and 
then according to the plasma concentration of acenocoumarol , dose can be adjusted 
depending on individual patients.13 
 With this background the aim of our study is to compare INR with plasma 
concentration of acenocoumarol  taken at trough and C max levels of Acenocoumarol  
in blood for optimal dosage to prevent sub-therapeutic/ supra-therapeutic drug 
therapy leading to life-threatening complications in patients with mechanical heart 
valve replacement of patients  
 
 
 AIM  
To study the association between acenocoumarol  levels in blood and INR values in patients 
who have undergone cardiac valve replacement. 
 
OBJECTIVE  
1. To find out the trough and peak levels of acenocoumarol  in blood in patients with 
normal INR (2.5-3.5) and patients with extremes of INR (1.5-2.5 and 3.5-4.5). 
2. To find out the association between INR of three groups (low, normal and high 
INR) and their respective plasma concentration of acenocoumarol  taken at 
trough and Cmax concentration. 
3. To compare between trough plasma concentration of patients with low and 
high INR    with trough concentration of patients with normal INR.  
4. To compare between Cmax plasma concentration of patients with low and 
high INR with Cmax concentration of patients with normal INR.  
5. To compare the trough plasma concentration of acenocoumarol  of patients 
with INR 1.5-4.5 (all the three groups)  
6. To compare the Cmax plasma concentration of acenocoumarol  of patients 
with INR 1.5-4.5 (all the three groups).   
 
 
 
REVIEW OF LITERATURE 
 
RHEUMATIC HEART DISEASE (RHD) 
 
RHD is one of the preventable heart disease .Rheumatic heart disease is the 
most common cause of mortality in patients with heart disease. RHD is rare in 
developed countries. In the high economic countries patients with RHD are usually 
migrants.1 Social and financial alterations in developing countries have a positive 
outcome but major drawback is burden of disease in this area has been doubled. In 
these developing countries there is a good improvement in health systems. But 
prevalence of communicable and non – communicable disease plus tobacco 
addiction, diabetes, hypertension and heart disease has drastically increased.14RHD 
occurs as consequence of infection by Streptococcus pyogenes causing permanent 
damage to heart valves due to aberrant immune response .15 
 
PREVENTION OF FIRST EPISODE STREPTOCOCCAL INFECTION 
In 1995 committee was formed for preventing Rheumatic pyrexia. Group A 
beta streptococcus (GAS) and tonsillopharyngitis (strep throat) usually determines 
repeated infection of Rheumatic fever. First step in preventing Rheumatic fever is 
done by detection and diagnosis of Rheumatic fever as early stage. Also by initiating 
appropriate antibiotic cover. Proper anti-biotic cover helps in preventing secondary 
occurance.16 17 18 19 & 20  
 DIAGNOSIS OF STREPTOCOCCAL INFECTION  
Symptoms suggestive of Group A Beta Streptococcus are rapid onset sore 
throat, pain during swallowing, pyrexia in high degree with headache, abdominal 
discomfort, also vomiting sensation and vomiting especially in children. Added 
symptoms are erythema in tonsillopharyngeal area, lymphadenitis in anterior cervical 
region, petechial in soft palate with rash as scarlatiniform. Clinical finding in children 
are usually not reliable and present with discharge from nose. 
Only detailed history with clinical examination can guide physicians to 
differentiate GAS pharyngitis from pharyngitis produced by other pathogens. Throat 
culture or test like rapid antigen detection done by microbiological confirmation are 
required to conclude the diagnosis as GAS pharyngitis. 
Compared to children, adults have lower incidence for GAS infections. Risk 
for first attack of acute rheumatic fever is low in adults when compared to children, 
recent suggesting are clinical symptoms can be used to confirm a case of GAS 
pharyngitis in adults but this criteria cannot be followed in children.21   Irrational 
antibiotic treatment in adults who are not infected with streptococcal pharyngitis is 
not advisable.22 ,23,24 
CULTURE FROM THROAT 
Diagnosing from culture obtained throat is the traditional method used to 
confirm GAS pharyngitis. Good swab obtained from posterior pharynx and the 
tonsils in patients with GAS pharyngitis and in these patients if they did not get 
appropriate antibiotic cover, their culture will be strongly positive. This positive 
culture will help physician to come to conclusion.  
 
IDENTIFICATION OF ANTIGEN 
For identification antigen of GAS multiple tests are available. Some tests are 
specific, but sensitivity of these tests were found to be minimal. In patients with 
sudden onset of sore throat have rapid antigen detection testing positive, confirms 
GAS pharyngitis which is long duration. But if rapid detection test is not positive, 
clinicians cannot come to conclusion if pharyngitis caused by GAS is present.22, 25   
  Detection of antigen using blood agar plates was found to be more accurate. 
Shortly advanced tests are identified for identification of antigen, when compared 
with test like rapid antigen detection.26, 27 Clinicians are trying to find out whether 
blood agar or rapid antigen detection testing is more appropriate from their results 
and neglecting culture from throat.  
 
TESTING ANTIBODIES FOR STREPTOCOCCAL INFECTION 
Detection of antibodies for streptococcal infection were done in olden days. 
This test gives immune reaction which took place long time before. This method of 
antibody detection is deficient in diffenciating whether patient is carrier of GAS 
infection in pharynx or positively affected by infection. But if this antibody values 
are positive and elevating will help us to come to idea that individual is suffering with 
pyrexia of rheumatic in origin. Assays identifying antibodies like antistreptolysin O 
and another antibody like antideoxyribonuclease B are routinely used. By doing this 
procedure clinicians can find out   that whether   person is a case of acute 
glomerulonephritis or a case rheumatic fever which is acute in origin. Antibody 
which is detected initially is antistreptolysin O.Antideoxyribonuclease B values are 
done only if first test is negative. Initial antistreptolysin O are elevated within one 
week after infection and reaches high value by around 3 to 6 week of infection. Both 
laboratory values are high even after GAS which are not complicated. Identification 
of both antibodies test is by assays like neutralization. But recent procedures like 
latex agglutination are nephelometric. Only traditional have efficient standard values 
than recently developed investigations.28, 29     
Clinicians should know positive and draw backs of these lab tests which will 
guide them in coming to conclusion. One more investigation is slide agglutination 
which is used for identifying antibodies, main drawback for this is proper 
standardsation is not available. So this investigation is neglected now.  Anti-deoxy 
ribonuclease B titres begin to rise 1 to 2 weeks and peak 6 to 8 weeks after the 
infection. Elevated titres for both tests may persist for several months after even 
uncomplicated GAS infections. 30, 31 
 
APPROPRIATE TREATMENT FOR RHEUMATIC FEVER 
Efficient treatment is needed for treating rheumatic fever. Criteria to be 
considered while treating are symptoms and bacterial capability. Treating clinicians 
must have sound idea about the spectrum covered by selected drug and possible 
adverse drug event that agent is capable. It is difficult to find a combination which 
can completely clear GAS from pharynx. But it has been proved beta lactam agents 
like penicillin and cephalosporins can be used for GAS infection. Usual drugs used 
are benzathine penicillin and penicillin V, unless patients are sensitive to these drugs. 
Repository penicillin which is given intramuscular, demonstrated to prevent first 
attack of rheumatic fever which is rapid in onset.32, 33     
Drug with narrow spectrum, good capability and cost effective is penicillin.9 
days after onset of acute illness, penicillin if started guard’s against primary onset of 
rheumatic fever.34      
Diagnosis done early by rapid antigen test and initiation of therapy will 
decrease contagious period and help person to do normal task early .If one day or 24 
hours antibiotic cover is over then that patient is said be non-infectious.35 
 
ROLE OF ORALPENICILLINS 
Penicillin V and amoxicillin are commonly used. Trials have shown penicillin 
V dose used 40mg / kg, which should not be more than 750 mg in patient who weighs 
27 kgs in one day is given in three doses. Dose for children is 250mg given twice a 
day.36, 37 Even though patients are not symptomatic They are advised to take 
medications for at least 10 days. 
 
 
 
DEVELOPMENT OF RHEUMATIC HEART DISEASE 
Repeated episodes of   Rheumatic fever causes the damage to the heart valves 
which results in Rheumatic Heart Disease. The affected valves become scarred and 
stretched which prevents them from moving normally, resulting in stenosis or 
regurgitation. Type of lesion and severity of the disease among the affected individual 
are determined by several factors. The key determination of disease pathogenesis in 
Rheumatic Heart Disease are the genetic susceptibility and environmental factors like 
low socioeconomic status. The effect of environmental factors on the pathogenesis of 
the disease varies from one population to another population. Symptoms of 
Rheumatic Heart Disease depends on the value affected and its severity. Symptoms 
due to Rheumatic Heart Disease occurs only when the valvular disease becomes 
severe. 38 
           Patient is said to be positive for Recent GAS infection if the patient has 
throat culture which is positive, raised levels of anti-streptococcal anti-bodies will 
denote of recent scarlet infection. 
Early detection and diagnosis of Rheumatic heart disease is important to prevent 
progression of this valvular disease of heart.38 
RHEUMATIC HEART DISEASE AND SYMPTOMS 
Patients with rheumatic heart disease frequently have symptoms like breathing 
difficulty, feeling tired and signs of failing heart. 38 
DIAGNOSTIC CRITERIA FOR RHEUMATIC FEVER 
          For the diagnosis of rheumatic heart disease according American Heart 
Association modified Dr T Duckett Jones major and minor criteria are used which are 
given below, 
Major criteria 
 Carditis 
 Arthritis 
 Sub cutaneous nodules 
 Erythema marginatum 
 Chorea 
Minor criteria 
 Fever 
 Arthralgia 
 Elevated sedimentation rate 
 C reactive protein 
 Prolonged PR interval in electrocardiogram 39. 
RHEUMATIC HEART DISEASE AND COMPLICATIONS  
          Repeated Rheumatic fever leads to damage valves in heart and causes 
Rheumatic Heart Disease. Valves become stretched and tight which resists the 
movement to cause regurgitation or stenosis. If the above condition missed and 
appropriated drug therapy neglected will cause heart failure and premature mortality.  
38 
 
FREQUENT PROBLEMS IN RHEUMATIC HEART DISEASE 
Patients with Rheumatic heart disease should be treated to prevent complications. 
The patients with untreated Rheumatic heart disease have the compilations like, heart 
failure (46.9%), pulmonary hypertension (32.7%).atrial fibrillation (13.9%). 
rheumatic fever causing frequent acute infection and finally inflective Endocarditis 
(4.5%) . 
 
VALVES AFFECTED 
The most common valves affected by rheumatic heart disease are 
1, Mitral (70%) 
2, Aortic valves (30%) 
          The frequent valve lesion are mitral regurgitation, mitral and aortic 
regurgitation, mitral stenosis and mixed valve disease are next common lesions 6 
RHEUMATIC HEART DISEASE AND ACENOCOUMAROL   
In patients with Rheumatic Heart Disease the following are the indications for 
oral anticoagulant therapy: 
 Rheumatic valve Disease 
 Mitral valve disease 
 Aortic valve disease 
 Mitral stenosis 
 Mitral regurgitation 
 Mixed aortic and mitral valve disease. 
The main indication of oral anticoagulants in Rheumatic Heart Disease is to 
prevent thromboembolic events which may lead to serious complications like stroke. 
In this therapy vitamin k antagonist (VKA) plays a major role and available. 
Monitoring the dose of anticoagulant was done to increase efficacy and reduce 
hemorrhagic complications. 
    Vitamin k antagonists has limitations like slow onset of action, dose requirement 
which is variable, polymorphism which is common influencing pharmacodynamics 
or protein binding pharmacokinetic of VKA, dietary vitamin k intake found different, 
drug drug interactions is usually multiple. Even though vitamin k antagonists had 
many limitations, these are drugs used for   treatment of patients with valvular heart 
disease with artial fibrillation and cardiac valves which are mechanical. 
 Commonly used VKA 
 Warfarin 
 Phenprocoumon  
 Acenocoumarol   
 
INTERNATIONAL NORMALIZED RATIO AND RHD 
           Patients with valve disease have increased risk of clot formation and embolism 
which finally leads to stroke. For prevention of this complication anti-coagulant 
therapy is needed. Therapy with anti-coagulation blocks clotting and reduces 
occurrence of stroke. Anti-coagulation therapy dose is adjusted by estimating inter-
national normalized ratio (INR).INR compares clotting times in patients who are on 
anti-coagulation treatments with that of normal person’s efficiency and therapeutic 
dose of anti-coagulation depends on linear maintains of INR 39 ,40 ,41. 
 
MANGEMENT OF ADVANCED RHEUMATIC HEART DISEASE 
           Aortic and mitral valves are commonly affected by RHD. Next valve is 
tricuspid valve and finally pulmonary valve rarely affected .Atrial fibrillation occurs 
in high frequency in patients with Rheumatic heart disease which causes serious 
complication like emboli. Therefore patients with RHD required surgery. Mechanical 
valve and bio prosthetic valve are two procedures in RHD .The type of replacement 
surgery for a patient with Rheumatic heart disease depends on patient and health 
practitioner’s choice, disease condition and demographic factor.42  
ADVANTAGES OF MECHANICAL VALVE REPLACEMENT 
 The patients with rheumatic heart disease should be operated to prevent 
complications. Of the surgeries mechanical valve replacement is the surgery mostly 
preferred. The   advantages of mechanical valve replacement are long term durability, 
therapeutic anti-coagulant range can be maintained and chances of later re-operation 
is minimum. 42 
 
VALVE REPLACEMENT AND ACENOCOUMAROL  
          Acenocoumarol  and warfarin are effective in the treatment and prevention of 
thromboembolic disorders in the cardiac valve replaced patients. The coumarin 
derivative commonly used in many countries is acenocoumarol . Several factors 
alters the individual response to oral anticoagulants. These includes, 
THE TWO MAIN FACTORS 
1) GENETIC 
2) AND NON-GENETIC 
THE NON-GENETIC DETERMINANTS ARE  
 Age 
 Gender 
 Body mass index (BMI). 
 Diet 
 Concurrent medication 
 Intake of vitamin K. 
 Patients compliance 43  
            Acenocoumarol  is an anti-coagulant effective in treating and preventing 
thromboembolic events in the cardiac valve replaced patients.44 
ACENOCOUMAROL          
The oral anticoagulant used worldwide are vitamin K antagonists. Vitamin K 
antagonists act by inhibition of vitamin k epoxide.44 
    Acenocoumarol  is the commonly used vitamin K antagonists.8,9 Anti-
coagulant Acenocoumarol  inhibits action of vitamin K on gamma acid-carboxylation 
of certain glutamic acid molecules, located in the coagulation factor II ( Pro-
Thrombin ) , VII , IX , X and protein C and S in the liver. Because of this inhibition 
no blood clotting can be initiated. 
TARGET SITES OF ACENOCUOMAROL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY 
                       CLOTTING CASCADE 
                       ACENOCOUMAROL  44 
Xla VIla 
IXa 
XIIa 
Xa 
 
Acenocoumarol Thrombin 
Fibrin 
Va 
     Acenocoumarol  rapidly absorbed from the gastro- intestinal tract, peak 
concentration (Cmax) of 0.3 mcg/ml in 2-3 hours. Acenocoumarol  is highly bound to 
serum proteins and only 1.52% of the drug is free. 44 
 Bioavailability – 96% 
 Protein binding – 98% 
 Metabolism – hepatic (mainly through CYP2C9) 
Terminal elimination half-life – 8- 11(shortest) 
Excretion- mostly renal.   
 Patients with polymorphism in CYP2C9 and VKORC1 had increased incidents of 
over anticoagulation (almost up to 74%) and decreased risk for mild anticoagulation 
(up to 45%). Diet containing vitamin K in form of Vitamin K1 or phylloquinone in 
leafy vegetables was variable between patients and Vitamin K in form of menquinone 
or K2 was produced in the colon by bacteria was also variable in patients, these varied 
dietary intake of vitamin K alters international normalized ratio which is the usual 
laboratory investigation used for evaluating the dose of vitamin K antagonists 
(VKA). Therefore recommendations about diet was given to patients who were on 
VKA.44 
 
DIFFERENCE BETWEEN ACENOCOUMAROL  AND WARFARIN 
 Acenocoumarol  is completely and rapidly absorbed from stomach. 
Acenocoumarol  and warfarin are structurally different. Nitro group in para position 
in phenyl ring is the difference. It was proved that acenocoumarol  has good 
performance rate in maintaining International Normalized Rate within therapeutic 
range when compared with warfarin. 44. 
 
ONSET OF ACTION OF ACENOCOUMAROL  
 Acenocoumarol  has rapid onset of action, with 15-20 hours of duration of action. 
Hypoprothrombinemia caused in most of patients is almost after 36 hours after the 
first dose of acenocoumarol . Even though half-life of acenocoumarol  is short, after 
attaining steady state pharmacodynamics feature is found to be stable.   Around 1.52 
% of drug is only free in plasma .Remaining is highly bound to serum proteins.  After 
drug is given orally maximum raise in prothrombin time is seen 24 – 30 hrs.44 
 
SAFETY AND EFFICACY OF ACENOCOUMAROL  
 Safety and efficacy of acenocoumarol  has been studied in varied conditions 
requiring treatment and prophylactic treatment of thromboembolism like  
1. Atrial fibrillation  
2.  Cardiac valve replacement 38 
Thromboplastin time test is prolonged from 36 to about 72 hrs depending on 
the therapeutic dosage given to that individual. When drug is withdrawn 
thromboplastic-time returns to normal. The dose of Acenocoumarol  ranges 
from 1 to 8 milligrams. Usual starting dose of Acenocoumarol  is 2mg for 
person within normal weight range 45.Acenocoumarol  is rapidly absorbed 
after ingestion with 60% minimum as systemic bioavailability. Cmax is 
reached within 1-3 hrs.’ after the dose. AUC valves of plasma-concentration 
versus time in proportional to dose given. Most of drug remain bound to 
plasma protein (98.7) that is albumin. Acenocoumarol  is primarily 
metabolized by CYP2 C9 enzyme. Secondly by CYP1 A2 and CYP2 C19 
Plasma half-life is 6.26 to 14.22. Anti-coagulant activity of R (+) enantiomer.   
Dose excreted in urine is about 0.12 - 0.18% which is unchanged in urine. 
Excretion of cumulative metabolites of unchanged active substance takes 
approximate period of 8 days. Of which is 60% dose in urine and 29% of dose 
in faeces 46. 
 
ACENOCOUMAROL  DOSE 
           To maintain Acenocoumarol  dose with in therapeutic range the following 
were considered, 
 Demographic Data. 
 Indication of Anticoagulation therapy. 
 Concurrent Medication. 
 Diet (Vegetarian or Non-Vegetarian). 
 Any episodes of bleeding. 
 Most important INR target range. 
           Acenocoumarol  is one of life saving drug. But therapeutic index in narrow. 
Major adverse effect is increased risk for profuse bleeding. To prevent this serious 
side effect regular and repeated measurement of International normalized ratio (INR) 
of prothrombin time is a must during treatment with Acenocoumarol . Commercially 
available Acenocoumarol  is racemic mixture of roughly equal amount of (R) and (S) 
Enantiomers. S acenocoumarol  is more patient enantiomer. It almost tenfold higher 
when compared to R-acenocoumarol . Elimination half-life of S-acenocoumarol  in 
substantially shortened (1.8h) while R-enantiomer (6.6h) reaches much higher 
concentration in plasma when compared with later .Because of the above reason anti-
coagulation effort is mostly due to R-acenocoumarol , even though S-acenocoumarol  
has better intrinsic anti-coagulant activity 47,48. 
           Enantiomers of Acenocoumarol  differ in pharmacodynamics and 
pharmacokinetics features but Racemic Mixtures contain equal parts of R (+) and S 
(+) enantiomers.  Measurement of Acenocoumarol  in plasma can be done by using 
non-enantiomers assay 46. 
 
FACTORS INFLUENCING EFFECTS OF ACENOCOUMAROL  IN A 
PATIENTS 
There are varied factors affecting the effect of acenocoumarol  drug in  
patients. These are the following important factors. 
 Polymorphism [Genetic] 
 Non-Genetic 
 Ethnic  
 Still unknown reasons 
 
 GENETIC INFLUENCES 
            Well known genetic factor contributing to variation of Acenocoumarol  
therapeutic dosing CYP4F2 genes. Gene polymorphism plays an important role in 
dose requirements of Acenocoumarol  .The contribution of gene polymorphism is 
influencing dose of Acenocoumarol  within therapeutic range was also evaluated in 
North Indian valve replaced patients. 
NON-GENETIC FEATURES  
 Age, gender, BMI (Basal Metabolic Index), intake of vitamin K, concurrent 
medications and compliance of patient are the non-genetic factors which alters the 
acenocoumarol  dose in the paients.49Influence of age on dosing of Acenocoumarol  
is varied. Activity of cytochrome (P450) enzyme in body reduces with advancement 
of age which resulted decrease in Acenocoumarol  dose is elder patients. Decreases in 
0.5 to 0.7 mg per 10 yrs. which independent of genetic polymorphism and height of 
patient, while an opposite trend was elicited in other group of patients 50 
            In a study done in North part India it was proved that dose is decreasing with 
increase in age. But this finding was not significant statistically. (P=0.47).     Another 
finding in this study was sex of patient did not significantly after dose requirements 
of Acenocoumarol . But there are studies to prove that female patients required quite 
large dose of daily maintenance dose of Acenocoumarol . But these are studies which 
showed Acenocoumarol  dose did not vary according to gender 51. 
 
           Acenocoumarol dose was  influenced by drug drug interactions. To obtain 
stable constant anti-coagulation above factor should also be considered 49.Co-
administered medications which plays important part in medication for patients was 
also evaluated, it was found that patients on Amiodarone as concurrent medication 
did not show significant variation in Acenocoumarol  dose ( P=0.12 ) .Patient on 
atorvastatin also showed the similar finding ( P=0.5 ) But physician must be cautious 
in interpreting above result because patients on Amiodarone and Atorvastatin group 
was minimum.  But these studies which proved using statin with Acenocoumarol  
caused slight reduction in dose in daily routine dose of later 50. 
            There are also studies showing co-administered drugs did not cause 
significant changes in Acenocoumarol  maintains dose. No difference was seen in 
Acenocoumarol  therapeutic dose in patients with concurrent medication and those 
without any added drugs 52. Consumption of diet rich in vitamin K (e.g.: Green 
Vegetables) will cause reduction in anti-coagulant efficacy 53. 
            Flora of gut is altered by initiation of some antibiotics which will result in 
exaggeration of anti-coagulant repose to coumarins 54.One of parameter included in 
prediction of dose of Acenocoumarol  is BMI. But study done in Northern part of 
India which grouped patients into two groups according to BMI elicited that no 
significant correlation was found with BMI and dosing of Acenocoumarol  55. 
            Yet another factor determining requirements of Acenocoumarol  is 
compliance. In a non-compliant patient dose of Acenocoumarol  need to get a 
therapeutic repose in varying which caused longer time to reach stable INR. When 
compared to patients with normal compliance 56. 
 
INTERNATIONAL NORMALIZED RATIO (INR) 
             Oral anti-coagulant treatment is normally monitored by international 
rationalized ratio (INR). Which is followed worldwide. 
Oral anti-coagulation is an important drug in patients  
 After heart valve replacement. 
  With Rheumatic Heart Disease. 
 With Atrial Fibrillation. 
 With Deep Vein Thrombosis. 
              Most common adverse effort in these patient on oral anti-coagulation 
therapy is massive hemorrhage or thromboembolism which develops when the anti-
coagulant drug is not in therapeutic range. Anti-coagulation response individuals 
varies which makes a regular monitoring is compulsory to prevent complications. 
These are huge variety of parameters related to coagulation. But the parameter which 
directly shows rate of thrombin generation is Prothrombin Time (PT) 57. 
              Number of studies have shown that concentration of factor 11 (F11) is 
linearly related to rate of thrombin production. Prothrombin time is commonly 
expressed as International normalized Ratio just to avoid bias form variations among 
coagulation analyzers (System Derived) and source of reagent (Different batches of 
thromboplastic)57 Link between INR values and various factors of coagulation is still 
inconsistent assaying clotting factors FII , FVI  and FX frequently affects 
prothrombin time ( INR ) protein C and Prothrombin fragments F1 + 2 had no 
prominent impact on variation of INR which was proved by RS Ratio of Activated 
Partial Thromboplastic Time ( APTT ) or fibrinogen 58.  
            Despite careful and well-organized care and frequent laboratory control, the 
INR of patients are not within the therapeutic range due to several interfering factors 
such as co-medication changes, interfering diseases and changes in diets. INR outside 
the therapeutic ranges are associated with an increased risk of bleeding complications 
or thrombotic episodes59   
 
COMPLICATIONS DUE TO INAPPROPRIATE DOSE OF 
ACENOCOUMAROL           
  Most common adverse effort of anti-coagulation with oral coumanin 
derivatives in bleeding complication. In these patients therapeutic failures is also 
common. Around 2 - 5% of patients on oral anti-coagulant treatment experience 
serious bleeding every year. While 0.5 - 1% of patients have eposide of fatal bleed. 
Only because of narrow therapeutic range of INR and dose which has high variability 
to attain anti-coagulation is the main reasons for complications. To reach the target 
INR repeated INR checks are needed. Depending on INR doses are changed. 
            According to Gadisseur et al.  patients on acenocoumarol  treatment during 
initial first 6weeks of anti-coagulation are maintained in therapeutic range for 30% 
.Because of this long term to acheive stable and effective INR, adverse effects like 
bleeding are more common during first month of anti-coagulation initiation. Above 
finding was described by landefeld et al. Episode of Bleeding and rates of 
thromboembolism directly correlates with time within therapeutic range.45 
Study was conducted to confirm initial doses 2-6 mg Acenocoumarol  given to 
patients would predict maintenance dose of oral anticoagulant therapy in terms of 
normal range of INR.  Above study proved only around 76% of patients had INR 
were within adequate range. While approximately 13% of Patients had range higher 
than therapeutic range. 7% of patients had INR below range, all these findings were 
dose independent. This study proved that INR value and required dose of 
acenocoumarol  had inverse relationship. Another additional findings in this study 
was anticoagulation dose for elder patients must be less when compared with 
youngers.59 
The maintenance dose of acenocoumarol  varies in individual patients which is 
determined by multiple factors as discussed above. Therefore estimation of 
acenocoumarol  in plasma of patients will be more accurate and precise for the dose 
adjustment of acenocoumarol .13  
THERAPEUTIC DRUG MONITORING [TDM] 
Monitoring of plasma concentration of drug for adjusting dose is called 
TDM.TDM helps in maintaining drug doses according to individuals by keeping 
plasma drug concentration in blood within therapeutic window or range.TDM helps 
in finding out efficacy and safety of a medication in varied number of clinical 
settings. This is done by combining knowledge of pharmaceutics, pharmacokinetics 
and pharmacodynamics. Main goal of TDM process is to formulate doses according 
to individuals to get optional benefit for patient. To analyse TDM pharmacokinetic 
principles are used by pharmacologists and clinical pharmacists. 
 
Clinical pharmacokinetic monitoring was supported by drug concentration – 
response relationship, pharmacokinetic properties were mapped, invention of 
computerization which was high throughout had more positive growth in 
analytical technology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STEPS IN ACHIEVING DECISIONS IN DOSE WITH THERAPEUTIC 
DRUG    MONITORING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIRM 
DIAGNOSIS 
ADMINISTRATION OF DRUG  
APPROPRIATE 
DRUG SELECTED 
DOSE OF DRUG ADJUSTED 
TO ACHIEVE TRGET 
PLASMA CONCENTRATION 
ASSESSMENT OF PATIENT DETERMINATION OF DRUG 
CONCENTRATION 
APPLICATION OF PHARMACOKINITIC 
MODEL THEN JUDGEMENT DONE 
IF NEEDED DOSE 
ADJUSTED 
Plasma concentration measurement will be useful, that is patients with low 
level shows compliance which is poor or patient is under treated. If previous 
estimation of plasma concentration revealed to be high or drug which is prescribed 
usually does not cause low concentration, then poor compliance is implicated. 
Measuring drug levels in blood will make physician work little easy to start drug 
therapy and later tailor dose according to individual. 
 
This method is important for drug with narrow therapeutic range like 
 Digoxin 
 Phenytoin 
 Lithium 
 Theophylline 
 Anticoagulants 
 Cyclosporine 
 Aminoglycoside antibiotics. 
 
If a need for adjusting dosage during course of treatment in patients with kidney 
disease, estimating blood levels will be useful. If there is a poor clinical response for 
a well-established disease then under treatment is considered. It will be difficult to 
monitor an effect when a drug is used for prophylaxis. In this stage, treating 
physician can choose a dose that is capable of producing target plasma concentration. 
This is common with preventing manic depressive attacks with lithium, to prevent 
epilepsy after trauma or neurosurgery with use of phenytoin and cyclosporine which 
is used after transplant, to avoid rejection of transplant. In all these conditions 
concentration of drug in plasma is done in early stages of treatment to protect patients 
from toxic plasma concentration. Therefore in this case confirmation can be done by 
TDM. 
THERAPEUTIC RANGE CONCEPT 63 
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CONCENTRATION 
 
 
 
 
        TOXICITY RISK INCREASED 
 
 
 
THERAPEUTIC RANGE                 WE CAN 
EXPECT                                            
                                                               
THERAPEUTIC RESPONSE 
 
 
SUB THERAPEUTIC EFFECT 
 
 
 THERAPEUTIC DRUG MONITORING AND MEASURING DRUG 
CONCENTRATION IN PLASMA 
Because of the variability of pharmacokinetic  differences estimating steady 
state drug concentration and modification of dose to reach needed concentration is 
effective .There are limited number of drug formulation, which has good relation 
between blood levels and dose response curve. In this case measuring blood 
concentration will be an important surrogate index. Therapeutic drug measuring is 
only portion of TDM that gives perfect clinical interpretation of drug levels and this 
is done on pharmacokinetics base principles. To ensure full benefits in clinical cases, 
correct interpretation of plasma concentration is main tool. 
Physicians evaluate pharmacodynamics of drug by therapeutic changes such as 
lipid profile blood sugar ,blood pressure and  then by blood coagulation and clotting. 
Main drawback is there are many drugs which does not have readily available 
measures or procedure. Thus stages of TDM is predicted on basis that there is strong 
relation between drug formulation and concentration of drug in blood. Another 
existing relationship is between concentration of drug in plasma and its 
pharmacodynamics effect. 
PHARMACOKINETICS AND PHARMACODYNAMICS RELATIONS AND 
CONDITIONS THAT INFLUENCE THEM 
 
 
 
 
 
 
  
 
ROUTIENLY 
PRESCRIBED 
DOSE 
STATE OF DRUG AT 
SITE OF ACTION 
OR BLOOD LEVELS 
EFFECTS DUE TO 
DRUG OR 
CLINICALLY 
PRODUCED EFFECT 
VARIATION IN 
PHARMACOKINETICS 
1. Patients compliance 
2. Errors in dose or medication 
3. Mass and volume of body fluid 
and tissue 
4. Interactions between drugs  
VARIABILITY IN 
PHARMACODYNAMICS 
1. Status of drug receptor  
2. Pharmacogenetic factor 
3. Drug Drug interactions  
4. Tolerance   
THE CRITERIA A DRUG SHOULD FULLFILL   FOR CONCENTRATION  
MEASUREMENTS IN PLASMA TO BE EFFECTIVE 
 Clinical evidence that show therapeutic or toxic side effects. 
 Concentration in blood level and desired or adverse effect which is toxic or 
both have effect   relationship. 
 Therapeutic range being low. 
 Important active metabolites are not metabolized. 
 
REQUIREMENTS OF THERAPEUTIC DRUGS MONITORING 
Requirements of therapeutic drugs monitoring are Pharmacokinetics, 
Pharmacodynamics and Laboratory Analysis. 
 
 TO ATTAIN GOAL IN THERAPEUTIC DRUG MONITORING 
 Identifying nature of problem to be solved. 
 Appropriate matrix selected. 
 Select methodology to solve the conditions. 
 Valid analytical schemes developed which are performed accurately with 
quality which in good and interpretation within the framework of clinical 
problem. 
 
 
 
STEPS TO BE FOLLOWED TO GET DEFINITIVE PLASMA 
CONCENTRATIONS 
Care and attention must be given for timing of blood sample. 
 Type of blood sample used for analysis. 
 Technique used for measurement. 
 Interpretation and analysis of results. 
     Laboratories which do drug testing routinely have developed assay procedures for 
high performance liquid chromatography (HPLC). 
     Treating clinicians should consider not only blood plasma concentration but also 
features which are seen clinically. Doctors must be familiar with the analysis plasma 
concentration of patient. Critical importance should be given to demographic 
characters of patient like patient's age, disease condition, ethnicity and variation in 
pharmacokinetics and pharmacodynamics between individuals. 
PLASMA SAMPLE AND TDM 
To estimate concentration in plasma accurately, team of TDM must be 
informed in relation to last dose given when sample was collected and when drug 
regimen was initiated.  Life threatening complications can be solved and treated by 
estimating peak plasma concentrations within 1 to 2 hours after a oral dose serum 
concentrations of almost all drugs peaks. Conditions which cause slow or delayed 
absorption can significantly slow time at which serum peak concentrations are 
reached. 
Trough blood levels are least affected by absorption and problems of distribution. 
If a patient is on a drug for a long period, there is chance of drugs and 
metabolites to accumulate in body. It is said “steady state “is achieved when 
amount of drugs administered in equivalent to quality of drug eliminated. The 
requirement to attain this steady state depends directly on half-life of drugs. About 
95% of drugs accumulates after 5 half-lives are completed, which shows  
steady state is reached. 
         If a loading dose is given blood levels which are equivalent to steady state in 
reached. Plasma concentrations should be monitored as often as  possible when 
toxicity is suspected. Similarly quick and immediate assays are appropriate when of 
therapeutic control is poor, as in a clinical condition like atrial fibrillation, where 
loading dose is helpful. 
Details of dose and duration of treatment are important to analyze results. For 
a good interpretation of blood levels which change often, the dose and time of drug 
taken and sample withdrawn time should be known. Since absorption varies after oral 
dose, blood sample must be collected in elimination phase, not in absorption or 
distribution phase. 
These is considerable variation in people in towards. 
 Absorption. 
 Distribution and  
 Elimination of Drugs 
 
 
Drugs like 
 Oral Anti-coagulant. 
 Phenytoin. 
 Digoxin. 
            Vary ten times or greater in steady plasma concentration in patients who are 
treated with same dose. These differences are 
 Maximum due to formulation of drugs. 
 Genetic variation of patients. 
 Disease condition. 
 Effects due to environment 
 Drug interactions. 
Advantages of measuring blood plasma levels 
 Helps clinicians to find correct dose for that individual patients. 
 To gain best therapeutic effect with reduced risk of toxicity. 
 Easy to measure toxic or therapeutic effect of drugs. 
 Added information about drug action can be obtained. 
 This helps to tailor dosage within correct therapeutic range. 
            Factors which alter the efficacy of parent drug for a known blood 
concentration in total blood are drug interactions, electrolyte imbalance, acid base 
balance patients age, bacterial resistance and capacity of protein binding. For a safe 
and effective therapeutic medication and adjusting individual dose TDM plays a vital 
role.60 
ACENOCOUMAROL AND HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY 
             Acenocoumarol  is usually monitored by prothrombin time. We have already 
discussed that there is no relation between INR and dose of acenocoumarol  and 
estimation of acenocoumarol  levels in plasma will be the appropriate method to 
monitor dose of drugs, Because INR can be raised even when there is no significant 
cause or disease condition. Acenocoumarol  therapeutic concentration in 32 – 39 µg/l 
64. This drug stimulates unwanted adverse efforts like bleeding if this therapeutic 
window in exceeded. 
 
ADVANTAGE OF ESTIMATING ACENOCOUMAROL  IN PLASMA 
 Helps in diagnosis. 
 Appropriate and effective treatment can be given for patient. 
 We can distinguish between compliant and non-compliant patient. 
 Patients with resistance to anti-coagulation treatments61 
 To find out any pharmacokinetic interactions on acenocoumarol  metabolism 
and / or its plasma protein binding capacity. To find out answers for these 
questions, correct and most sensitive analytical method is required to analysis 
acenocoumarol ’s stereo isomers. 
            HPLC methods has two stereo specific analysis methods for estimation of 
acenocoumarol . Using whelk-chiral stationary phase HPLC analytical method is 
useful in estimation of enantiomers of acenocoumarol . This study proved that HPLC 
is most sensitive analytic method for determination of acenocoumarol  in plasma. 
Performing characters of assay is most accurate and can be easily repeated. Results 
demonstrated by this method was found to be reliable and a procedure which is 
convenient for estimating plasma concentration of acenocoumarol  62, 63, 64 
Therefore we can justify our study saying that after heart valve replacement 
patients need chronic administration of acenocoumarol . Since acenocoumarol  has a 
narrow therapeutic index and dose varies according to individual which depends on 
various factors. This leads to frequent and repeated monitoring of INR, to prevent   
serious adverse effects .There are studies which proves INR is not reliable. Therefore 
estimating plasma concentration of acenocoumarol  will be more precise, accurate 
and reliable for dose adjustments of acenocoumarol  in order to prevent 
complications due to oral anticoagulation.      
 
 
 
 
 
 
 
 
 
 
METHODOLOGY 
ETHICAL APPROVAL 
 Study protocol and the written informed consent form was approved by 
Institution Human Ethics committee [IHEC] before starting of the study. 
STUDY CENTRE 
This study was done in the department of Pharmacology and the department of 
Cardiothoracic and Vascular surgery PSG Institute of Medical Sciences and Research 
in collaboration with the Pharmaceutical analysis department at PSG College of 
Pharmacy. 
STUDY POPULATION  
Outpatient from department of Cardiothoracic and Vascular surgery from 2015 
February to June 2016.  
 
INCLUSION CRITERIA 
 Patients who underwent mechanical heart value replacement. 
 Taking Acenocoumarol  2mg.45 
 Once daily dose. 
 INR  of 1.5 – 4.5.65 
 Patient’s with normal liver function. 
 Vitamin-K restricted diet. 
 Patients who have completed 3 Months of post operation convalescent period. 
EXCLUSION CRITERIA 
 Patients who have not completed 3 Months of convalescent period after 
surgery. 
 Patients with abnormal liver function. 
 Unrestricted vitamin-K diet. 
 Other major illness which lead to coagulation disturbance.  [Annexure-l]. 
 Patients on specified drugs which are known to produce inter action with 
acenocoumarol .            [ Annexure-2 ] 
 
 
 
Recruitment of Participants 
The details and purpose of the study protocol were explained to each 
participant individually and their doubts were clarified before obtaining informed 
consent. 
The informed consents forms provided to the participants were either in 
English or in Tamil. 
The participants who gave written informed consent and came under inclusion 
criteria were enrolled for the study. A copy of the consent form in attached in the 
annexure. 
STUDY DESIGN 
STUDY  DESIGN 
 
 
 
 
 
 
 
 TIMING OF THE BLOOD SAMPLE 
Around 2ml of blood was collected from the patients at the trough and Cmax 
levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood sample    
collected46 
Cmax level 46 
[Two hours after 
having the tablet] 
Trough level46 
 [Just before having 
the tablet] 
FLOWCHART OF METHODLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
          PATIENTS       
FULLFILLING 
INCLUSION CRITERIA 
INFORMED CONSENT 
PATIENTS ON 2MG ACENOCOUMARAL ONCE 
DAILY WITH INR OF 1.5 -4.5 
BLOOD SAMPLES 
COLLECTED 
TROUGH LEVEL 
CMAX LEVEL 
SAMPLES ANALYZED by 
HPLC of acnocumarol 
concentration 
 
  SAMPLE SIZE: 60 Patients. This study is a  pilot study. 
 
 
 
DEVELOPMENT OF UPLC METHOD OF HPLC FOR STANDARDISING  
ACENOCOUMAROL  AND LATER ESTIMATION OF ACENOCOUMAROL  
IN THE PLASMA OF PATIENTS 
Instrumentation and Chromatography conditions 
 
The UPLC instrument consisted of a Waters Acquity H class UPLC system 
equipped with a quaternary pump and 96-vial autosampler coupled with a diode array 
UV detector (Waters, Milford, MA, USA). The chromatographic separation was 
performed on an Acquity UPLC BEH C18 column from Waters (2.1 mm × 100mm; 
1.7µm). The column temperature was set at 35ºC and the autosampler was kept at 
10ºC. The mobile phase composed of a mixture of 25mM ammonium acetate buffer 
pH 3.5 adjusted with acetic acid (70%, v/v) and acetonitrile (30%, v/v) at a flow rate 
of 0.3ml/min. Before analysis the mobile phase was filtered through a 0.22µm 
membrane filter and degassed by ultra-sonificition. A 5µl injection of each sample 
was loaded on to the system and total analysis time was 8 min. DAD was set at 282 
nm. Data acquisition was done using Empower 3 software version 1.0 (Waters). 62 63 64 
 
SAMPLE PREPARATION AND ESTIMATION OF ACENOCOUMAROL  
CONCENTRATION IN PLASMA USING UPLC METHOD OF HPLC 
Sample preparation was carried out by the liquid-liquid extraction procedure and 
tetra -butylmethylether used as extraction solvent. Linearity was evaluated by linear 
regression analysis with different concentrations within the range 10 to 1200 ng/mL. The 
calibration curves exhibited excellent linearity with regression correlation coefficient (r2 > 
0.998) over the concentration range of 10 to 1200ng/mL. The percentage accuracy observed 
for the mean of back-calculated concentration for four calibration curves for the entire drug 
were within 95.28-103.71. 
 
 
 
 
 
 
 
 
 
 
 Representative Calibration Curve Plot for Acenocoumarol  
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Representative Chromatogram of Standard in Plasma 
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 STATISTICAL ANALYSIS 
The collected data were entered into SPSS version 19 for statistical analysis. 
• Pearson correlation was done to see the association between INR of 
three groups (low, normal and high INR) and their respective plasma 
concentration of acenocoumarol  taken at trough and Cmax concentra-
tion. 
 Unpaired t test was done to see relation between trough plasma concen-
tration of patients with low and high INR with trough concentration of 
patients with normal INR.  
 Similarly unpaired test was done to see relation between Cmax plasma 
concentration of patients with low and high INR with Cmax concentra-
tion of patients with normal INR.  
 One way analysis of variance (ANOVA) was used to compare only the 
trough plasma concentration of acenocoumarol  of patients with INR 
1.5-4.5 ( all the three groups )    
 Similarly One way analysis of variance (ANOVA) was used to compare 
only the Cmax plasma concentration of acenocoumarol  of patients 
with INR 1.5-4.5 (all the three groups).   
A  P Value of <0.05 was considered statistically significant. 
 
                                                
 
                                            RESULTS 
 
• Total of 56 participants were enrolled 
• These participants belongs to three groups of INR.  
• One group with low INR and these participants were 15 in number.  
• The participants with normal INR were 30 in number.  
• While participants with high INR was 11 in number. 
• It was found that there no complications or adverse effects in all 56 
participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 1: Distribution of Male and Female among valve replaced participants  
  
 
 
 Out of the 56 participants there were equal number of male and female 
participants.  (50% in each group - 28 in each group]. 
 
 
 
 
 
Fig 2: Distribution of the total participants 
 
 
 
 
 In our study there were more number of participants in age group of 40-60 
years. (70%).In the age group of 20-40 years the percentage of participants present 
were 23%. Above 60 years of age there were about 5% of participants, while below 
20 years there were only 2% of participants. 
Fig 3: Distribution of male and female patients in INR between 1.5- - 
2.5, 2.5 – 3.5 and 3.5 - 4.5 
 
 
 
 Males were more (15%) in low INR group while females were 9% In participants 
with INR 1.5 – 2.5 the male were around 18% and the females were 9%. Females 
were more in normal INR group and high INR group, 29% and 14% respectively 
while males were 25% and 5% in both groups. 
 
 
 
Fig 4: Distribution of sex in poorly controlled INR  
 
 
 
 
 50% of males and females were found in poorly controlled INR group [low INR (1.5-
2.5) and high INR group (2.5-3.5)  
 
 
 
 
 
 
 
 
 
 
Fig 5: Distribution of INR between 1.5 – 2.5, 2.5 – 3.5 and 3.5 – 4.5 
with reference to age 
 
 
 
  
In all the three groups of INR we found that maximum participants were in the age 
group of 40-60 years while participants with age group 20-40 years were the second highest. 
Least number of participants were above 60 years and below 20. 
 
 
 
Fig 6: Distribution of participants in poorly controlled INR with 
reference to age  
 
  
The maximum number participants  in poorly controlled INR [low INR (1.5-2.5) and 
high INR group (2.5-3.5 ) ] belong to the age group 40 – 60 ( 69% ) and 19% of 
participants were in the age group of 20 – 40 years. In the age group above 60 years 
12% of participants were present. 
Fig 7: Association between plasma trough concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 1.5 to 2.5 
 
 
 
 
  
Association between the trough concentration and INR 1.5 to 2.5 was 
compared. The highest trough concentration of 31ng/ml was in participant with INR 
1.87. While the lowest trough concentration of 13ng/ml was seen in participant with 
INR 1.78. 
  
 Fig 8: Association between plasma Cmax concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 1.5 to 2.5 
 
 
 
 
 
 Association between Cmax plasma concentration and INR 1.5-2.5 was analysed. 
Lowest Cmax concentration was found to be 32ng /ml in participants with INR 1.88 
and the maximum Cmax concentration of 88 ng/ml was seen in participants with INR 
2.1. 
  
 
Fig 9: Association between plasma trough concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 2.5 to 3.5 
 
 
 
 
 
 The association between trough concentration and INR 2.5 – 3.5 was analyzed. 
The highest trough concentration of 22 ng/ml was seen in participants with INR 2.82. 
While the lowest trough concentration was seen in patient with INR2.6 and 
concentration was 10ng/ml. 
 
 
Fig 10: Association between plasma Cmax concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 2.5 to 3.5  
 
 
 
Association between plasma Cmax concentrations of acenocumarol in participants 
with INR 2.5 - 3.5 was analysed .The maximum Cmax concentration was 120ng/ml while 
INR was 2.59. While the participant with INR 3.27 had the lowest concentration of 
28ng/ml/. 
 
Fig 11: Association between plasma trough concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 3.5 to 4.5 
 
 
 
 The association between plasma trough level plasma 
concentration of acenocoumarol  and INR 3.5 – 4.5 was analysed. The participant 
with INR 4.08 had maximum trough concentration of 19ng/ml, while a participant 
with INR 4.34 had the lowest trough concentration of 10ng/ml.  
Fig 12: Association between plasma Cmax concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 3.5 to 4.5 
 
 
 
The association between INR and Cmax plasma concentration of 
acenocoumarol  in participants with INR 3.5 – 4.5 was analysed .The lowest Cmax 
concentration of 45ng/ml was noted with INR 4.25, while the highest Cmax 
concentration of 92ng/ml was noted with INR 4.08.  
 
 
 
Fig 13: Association between   plasma trough concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 1.5 to 4.5 
 
 
 
 
             The association between INR and trough level plasma concentration of 
acenocoumarol  in participants with INR 1.5 – 4.5 (all the 3 groups) was analysed. 
The highest trough concentration of 29ng /ml was found in a patient with INR 1.88. 
The  a lowest trough concentration of 10ng/ml was in a participant with INR 4.25.  
 
 
 
Fig 14: Association between plasma Cmax concentrations of 
acenocoumarol  (in ng/ml) in participants with INR 1.5 to 4.5  
 
 
 
 
 
 
              Association between of INR and Cmax level plasma concentration of 
acenocoumarol  in participants with INR 1.5 – 4.5 (all the 3 groups) showed that 
participant with INR 2.59 had a Cmax concentration of 120ng/ml which was the 
highest. But a participant with INR 3.27 had 28ng/ml of Cmax concentration which 
was found to be the lowest. 
 
TABLE 1: MEAN TROUGH AND CMAX CONCENTRATIONS OF ALL 
THREE GROUPS: 
PLASMA 
CONCENTRATION 
PARTICIPANTS 
WITH INR       
1.5-2.5 
 
PARTICIPANTS 
WITH INR      
2.5-3.5 
PARTICIPANTS 
WITH INR     
3.5-4.5 
MEAN TROUGH 
CONCENTRATION OF 
ACENOCOUMAROL  
in ng/ml 
 
16.14 
 
18.79 
 
17.19 
MEAN Cmax 
CONCENTRATION OF 
ACENOCOUMAROL in 
ng/ml 
 
56.3 
 
59.1 
 
57.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 15: Comparisons of mean plasma trough concentration of 
acenocoumarol  (ng /ml) in participants with INR 1.5 – 2.5 and 2.5 - 
3.5 
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                 The comparison between mean trough plasma concentration of participants 
with INR 2.5-3.5 and participants with INR 1.5-2.5 was analysed. The mean trough 
concentration   was 16.14ng/ml with INR 1.5 and 2.5 while 18.32ng/ml was seen 
with INR 2.5 and 3.5  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig 16: Comparisons of mean plasma trough concentration of 
acenocoumarol  (ng/ml) in participants with INR 2.5-3.5 and 3.5-4.5 
 
 
 
Comparison of mean trough plasma concentration of participants with INR 2.5-3.5 
and 3.5-4.5 was done. The mean trough concentration   was 17.19ng/ml with INR 
between 3.5 and 4.5 while 18.32 ng/ml was seen with between INR 2.5 and 3.5  
 
  
 
 
 
 
 
 
 
 
 
 
Fig 17 : Comparison of mean plasma Cmax concentration of 
acenocoumarol  (ng/ml) in participants with INR 1.5-2.5 and 2.5-3.5 
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                   The comparison between mean plasma Cmax concentration of 
participants with INR 2.5-3.5 and 1.5-2.5 was done, which showed the mean Cmax 
concentration in both groups was similar.  
 
 
 
 
 
 
 
 
 
 
 
Fig 18: Comparison of mean plasma Cmax concentration of 
acenocoumarol  (ng/ml) in participants with INR 2.5-3.5 and 3.5-4.5 
 
 
 
 
                 
                   The comparison of mean Cmax of participants with INR 2.5-3.5 and 3.5-
4.5 revealed, that Cmax concentration between both the groups was almost the same. 
 
 
 
 
 
 
 
Fig 19: Comparison of mean INR of all groups (low, normal and high) 
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                 The mean INR of all the three groups (low, normal and high) was compared. The 
mean INR was 3.9 for High INR group, the mean INR was 3.12 for normal INR group, the 
mean INR was 1.97 for low INR group. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 20: Comparison of mean plasma trough concentration of 
acenocoumarol  (ng/ml) in participants with INR 1.5-4.5 
 
 
 
 
 
Only the mean trough concentration of all the three groups (1.5-2.5, 2.5-3.5 
&3.5-4.5) was compared and there was no significant difference between three 
groups.  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 21: Comparison of the mean plasma Cmax concentration of 
acenocoumarol (ng/ml) in participants with INR 1.5-4.5 
 
 
 
           The mean Cmax plasma concentration of all the groups of participants with 
INR 1.5-2.5, 2.5-3.5 and 3.5-4.5 was compared and there was no significant 
difference between three groups 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 Total number of participants for this study was 56. Participants did not found 
to have any complications or adverse effect due to acenocoumarol .  These 
participants belonged to three groups with different INR.  One group with low INR 
(1.5-2.5) and these participants were 15. The participants with normal INR (2.5-3.5) 
were 30. While participants with high INR (3.5-4.5) was 11. All these participants 
were on 2mg of acenocoumarol  for at least 3 months, before the sample was 
collected from them. Blood samples were collected from these participants at the 
trough and Cmax levels.  
         Acenocoumarol  is the most frequently used oral anticoagulant in valve replaced 
participants. This drug has a narrow therapeutic index .The most important and 
serious adverse effect of this drug is profuse bleeding which is life threating. To 
prevent this complication repeated and frequent estimation of INR is done. There are 
previous studies which confirms the variation of INR according to the laboratory 
tested. Studies also proves the inverse relation between INR and dose of the 
anticoagulant. There are studies which compared the relation between INR and 
plasma concentration of warfarin. These studies were done in Europe, China and in 
India 74, 75 76.  All these studies confirm that there is no association between INR and 
plasma concentration of acenocoumarol .   
                Our study is the first study to compare INR and plasma concentration 
acenocoumarol .   The aim of our study is to find out the relation between INR and 
plasma concentration of acenocoumarol . In our study we have compared INR of 
three different groups (low, normal and high INR) there plasma concentration taken 
at trough and Cmax levels respectively. The association between of trough plasma 
concentration of acenocoumarol  with three groups of INR was analyzed. Plasma 
concentration of acenocoumarol  at Cmax of all the three groups of INR was 
analyzed. 
               
DISTRIBUTION OF MALE AND FEMALE PARTICIPANTS AMONG THE 
VALVE REPLACED PAITENTS  
 There were equal number of participants in both the sex .They were 50 % in 
each group. In another study done in Indonesia participants with rheumatic heart 
disease, males were more and accounted for 95.2% while female were 4.8%.69      
(Fig 1) 
 
DISTRIBUTION OF VALVE REPLACED PARTICIPANTS IN REFERENCE 
TO AGE 
 In our study we had maximum number of participants in age group 40-60 
(70%).In the age of 20-40 yrs. the percentage of participants were 23%. Above 
60yrs of age we had only 5% of participants. While below 20 yrs, there were only 2 
% of participants. There is a study done in Australia which reveals maximum number 
of participants with rheumatic heart disease between 50.9 –71.4. In our study we have 
maximum number of participants in age group of 40 – 60 yrs.70. (Fig. 2) 
 
DISTRIBUTION OF MALE AND FEMALE PARTICIPANTS IN INR 1.5 – 2.5, 
2.5 – 3.5, 3.5 – 4.5. 
In RHD patients, males were maximum in participants with INR 1.5 – 2.5. In a 
study done in South India participants with low INR, female were more in number. 
But in our study we have more males. In participants with INR 2.5 – 3.5 and 3.5 – 4.5 
there were more females and they were 29% and 14% in each group respectively. 
While the participants with INR 2.5 – 3.5 there were 25% males. But in INR    3.5 – 
4.5 group males were only 5%.(Fig. 3) 
 In a study done in Netherlands, participants with INR between 2.5 – 3.5 and 
another group with INR    3 – 4 were taken. In these groups the number of males and 
females participants were 107 and 121 respectively.  Like our study, the study done 
in Netherlands also had more female participants.72 
 
DISTRIBUTION OF MALE AND FEMALE PARTICIPANTS IN POORLY 
CONTROLLED INR (INR 1.5-2.5 & INR 3.5-4.5) 
 In comparing the male and female ratio in participants with poorly controlled 
INR 1.5 – 2.5 and    3.5 – 4.5 there were equal number in both (50 %).Similar to this 
study, a study done in India showed participants who were receiving the maximum 
dose of acenocoumarol  > 4mg with low INR were females and another group which 
was receiving low dose of acenocoumarol  with high INR group were females But we 
had equal number of males and females with poorly controlled INR.(Fg.4) 
 
DISTRIBUTION OF INR BETWEEN 1.5 – 2.5, 2.5 – 3.5 AND 3.5 – 4.5 IN 
REFERENCE TO AGE 
 In all three groups of INR the maximum number of participants were in the 
age group 40 – 60 yrs. while the participants in age group of 20 – 40 years were the 
next highest. 
 According to a study done on RHD patients in India, more number of 
participants were in the age group of 30 – 45yrs with 43.68%. While the next highest 
was in the age group with 25.29% .But in our study we had more participants in age 
group of 40 – 60yrs.73. (Fig. 5) 
DISTRIBUTION OF PAITENTS IN POORLY CONTROLLED INR IN 
REFERENCE TO AGE 
  There were more participants in the age group of 40 – 60yrs (69%). 9% of 
participants were in the age group of 20 – 40yrs and above 60 years of participants 
were only 12% (Fig. 6) 
 
COMPARISON OF INR ALL THREE GROUPS (LOW, NORMAL AND 
HIGH) WITH THEIR RESPECTIVE TROUGH CONCENTRATION OF 
ACENOCOUMAROL  
          The INR (low, normal, high) of each was compared with their respective 
trough plasma concentration. Each comparison revealed that there is no significant 
correlation between INR and the respective trough concentrations. (P value >0.05) 
(Fig 7, 9 11). 
         Similarly comparison of total INR (1.5-4.5) with trough concentration also 
showed that is no significant correlation between INR and the trough concentrations 
of acenocoumarol . (P value >0.05) (Fig13). 
 
COMPARISON OF INR IN ALL THREE GROUPS (LOW, NORMAL AND 
HIGH) WITH THEIR RESPECTIVE Cmax CONCENTRATION OF 
ACENOCOUMAROL  
The INR (low, normal, high) of each was compared with their respective Cmax 
plasma concentration. Each comparison revealed that there is no significant 
correlation between INR and the respective trough concentrations. (P value >0.05) 
(Fig 8, 10, 12). 
Similarly comparison of total INR (1.5-4.5) with Cmax concentration plasma 
concentration of acenocoumarol  also showed that there is no correlation between 
INR and the trough concentrations of acenocoumarol . (P value >0.05) 
           Similar to our study there are studies showing the poor correlation between 
INR and plasma warfarin concentration.. They have found that there is no association 
between INR and plasma concentration of warfarin. They have discussed that 
concomitant medications, diet variations, seasonal changes and finally age are the 
factors which makes INR poorly dependent on plasma warfarin concentration.74    
From these observations it shows that there is no need to alter the dose of 
acenocoumarol  based on INR, since the concentration is similar        
 
 Another study done in Ethiopia, also explained that there was less association 
between plasma warfarin concentration and INR. They explained that numerous 
factors and inter-individual differences such as interaction with other drugs, 
resistance, diet, differing drug metabolisms, Vitamin K status, and other factors are 
the reasons for low cassociation. (Osman et al. 2005).81    
 A study done in China also proved the poor correlation between INR and plasma 
concentration of warfarin. All the above studies were done in different geographical 
location.75 
 A study done in Jipmer (South India) had concluded that participants with INR 
2 – 3.5 had no correlation between INR and plasma warfarin concentration. They 
have also said that warfarin has interindividual variation which makes the dosing 
problematic. Because of this interindividual variation some participants are sensitive 
to warfarin, and will require low dose of warfarin. Those participants who are 
resistant to warfarin .Therefore they will require a higher dose. 76 Warfarin plasma 
concentration measurement may be helpful in managing participants, especially those 
participants with ﬂuctuant INR and was those to manage.74, 75, 76, 81 
            All the above studies have the same conclusion as our study, which 
strengthens the concept that INR measurement alone would be only of limited value 
for dose-adjustment in participants with complicated situations.  There is a need for 
monitoring of plasma concentration before dose adjustment 
  
 
COMPARISION OF TROUGH PLASMA CONCENTRATION   OF 
ACENOCOUMAROL  IN PARTICIPANTS IN LOW AND HIGH INR GROUP 
WITH THE TROUGH CONCENTRATION OF PARTICIPANTS WITH 
NORMAL INR 
        Mean trough plasma concentration of acenocoumarol    of low and high INR 
group with the mean trough concentration of participants with normal INR were 
compared. There was no significant difference between trough concentrations of 
different groups it was all most similar as the P value > 0.05.(Fig 15,16 and Table 1 )  
 
COMPARISION OF MEAN Cmax PLASMA CONCENTRATION   OF 
ACENOCOUMAROL  IN PARTICIPANTS IN LOW AND HIGH INR GROUP 
WITH THE Cmax CONCENTRATION OF PARTICIPANTS WITH NORMAL 
INR        
    Mean   Cmax concentration of low and high INR group with the mean Cmax 
concentration of participants with normal INR were compared. There was no 
significant difference beween the comparisons showed it was similar as the P value > 
0.05.(Fig 15,16 and Table 1 ) 
  
COMPARISION OF MEAN INR OF THREE GROUPS  
                 The mean INR of all the three groups (low, normal and high) was 
compared. The mean INR was 3.9 for High INR group, the mean INR was 3.12 for 
normal INR group, the mean INR was 1.97 for low INR group. (Fig 19) 
 COMPARISION OF PLASMA MEAN TROUGH CONCENTRATION OF 
ACENOCOUMAROL  IN PARTICIPANTS WITH INR 1.5 – 4.5 
 Comparison of the plasma trough concentration of all the three group of INR 
(low, normal and high) was done. Even though these participants belong to various 
group of INR the trough level was almost similar. The participants with INR 1.5 – 
2.5, 2.5 – 3.5 and 3.5 – 4.5, had trough level as 16.14 ng/ml,18.79ng/ml,17.19ng/ml 
respectively. 
 The plasma trough concentration of all the three groups is similar as the P 
value is  > 0.05 (Fig 20 and Table 1) 
 
COMPARISION OF PLASMA MEAN C_max   CONCENTRATION OF 
ACENOCOUMAROL  IN PARTICIPANTS WITH INR 1.5 – 4.5 
 Participants with INR 1.5 – 2.5, 2.5 – 3.5 and 3.5 – 4.5 had C_max level as 
56.3ng/ml,59.1ng/ml,57.3ng/ml respectively. 
 The mean C_max of all the three group with different INR did not show any 
variation, they were almost similar. The plasma mean Cmax concentration of all the 
three groups is similar as the P value > 0.05.(Fig 21 and Table 1 ) 
  Vitamin K antagonists are effective oral anticoagulants drug in 
preventing and treatment of thromboembolic disease. These drugs have a narrow 
therapeutic range and shows inter and intra individual variability in dose requirement 
which is largely determined by both environmental and genetic factors. With the use 
of oral anticoagulant the dose response relationships are unpredictable. 
 So it is difficult to predict maintenance dose for acenocoumarol  which varies 
from 1mg to 56mg.79 The large variation in dose requirement is influenced mainly by 
pharmacokinetic and pharmacodynamics features.80In routine practice the dose 
adjustment for acenocoumarol is done by INR monitoring with acenocoumarol . But 
studies carried out   in four different zones in the world have concluded that there is 
poor correlation between INR and plasma warfarin concentration. 74 75 76 81 
                             Now in our study we have found a similar finding for acenocoumarol .We 
have found that there is no correlation between INR of three groups and plasma 
concentration of acenocoumarol .  (Trough & Cmax)   
   Monitoring INR alone, will have limited value for dose 
adjustment of acenocoumarol  as proved by other studies. The plasma concentration 
estimation of warfarin will be more appropriate for dose adjustments. 
 We have also found that there is no significant difference in plasma 
concentration in all three different group of INR 1.5 – 2.5, 2.5 – 3.5 and 3.5 – 
4.5.Which also confirms INR may not a reliable and appropriate marker for the 
adjusting dose of acenocoumarol . 
 So the measurement of acenocoumorol in plasma will be more accurate, 
precise and reliable method for the dose adjustment in patients compared to INR 
 
 
 
 CONCLUSION 
1. This is the first study to compare INR with plasma concentration of 
acenocoumarol  taken at trough and Cmax level. 
2. There was no correlation between INR and plasma concentration of aceno-
coumarol  taken at trough and Cmax level for all the three groups 
3. There was no significant difference between mean trough concentrations 
between three groups of INR 
4. There was no significant difference between mean Cmax concentrations 
between three groups of INR 
5. Therefore we can conclude that measuring INR alone, will have limited 
value for dose adjustment of acenocoumarol  as proved by other studies for 
warfarin 
6. Hence estimation of plasma concentration of acenocoumarol  will be ideal 
and appropriate for the dose adjustment of acenocoumarol . 
7. However the findings of this study has to be further confirmed with larger 
sample size for extremes of INR. 
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Annexure 1 
Major systemic illness causing coagulation disturbance 
 
Congenital: 
 
 Hemophilia 
 Factor 5 Leiden mutation 
 Protein C deficiency 
 Protein S deficiency 
 Von Willebrand's disease (vWD) 
Acquired: 
 
 Liver disease and cirrhosis 
 Shock 
 Sepsis 
 Malignancy 
 Renal disease 
 Prolonged steroid use 
 Anti-phospholipid antibody syndrome (APLAS) 
 Systemic Lupus Erythematosus (SLE) 
 
 Annexure 2 
Drugs Interactions with acenocoumarol 
 Allopurinol 
 Amiodarone 
 Azathioprine 
 Betamethasone  
 Carbamazepine 
 Cefoxitin  
 Cholestyramine 
 Cimetidine 
 Dexmethasone 
 Doxycycline 
 Erythromycin 
 Fenofibrate 
 Fluvostatin 
 Gingko biloba 
 Ibuprofen 
 Ketoconazole 
 Lovastatin 
 Orlistat 
 Quinine  
 Zafirlukast 
                         
ABBREVATIONS 
 
 
Rheumatic heart disease – RHD  
International Normalized Ratio - INR 
Oral anticoagulation - OAC 
Vitamin K antagonists - VKA 
Thromboembolic events - TE 
Therapeutic drug monitoring –TDM 
High –performance liquid chromatography – HPLC 
Nano grams per millilitre –   ng/ml 
 
 
 
 
 
 
 
 
 
 
 
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
I, , Dr. D. Jeyalakshmi  am carrying out a study on the topic: COMPRATIVE 
STUDY ON ESTIMATION OF ACENOCOUMAROL  LEVELS IN BLOOD IN 
PATIENTS WITH EXTREMES OF INR VALUES AND NORMAL INR VALUES 
AFTER VALVE REPLACEMENT SURGERY  as part of my research project being 
carried out under the aegis of the Department of PHARMACOLOGY. 
 
 My research guide is: Dr.S. Bhuvaneshwari, MD., Professor of the department, 
Pharmacology.  
 
 The justification for this study is: This study will be helpful in predicting op-
timal acenocoumarol dose requirements.  This study identifies patients at increased 
risk of supra-therapeutic INR (International Normalized Ratio) values and cere-
brovascular bleeding events. This allows personalization of dosing and to prevent 
cerebrovascular bleeding events 
The objectives of this study are 
 . Selecting patients with normal INR [2.5-3.5] and extremes INR [1.5-2.5 and 
3.5-4.5] after valve replacement surgery estimating acenocoumarol in blood. 
 Comparing levels of acenocoumarol in blood in patients with normal INR and 
patients with extremes of INR. 
Sample size:  60 
 
Study volunteers / participants are (specify population group & age group): Pa-
tients with INR 1.5 to 4.5 and who have undergone mechanical heart valve replace-
ment surgery at PSG Hospitals, Coimbatore, India 
 
 Location: The study will be conducted in the Department of Cardiothoracic & 
Vascular Surgery, PSG Hospitals, and Coimbatore, India 
 
We request you to kindly cooperate with us in this study. We propose collect back-
ground information and other relevant details related to this study. We will be carry-
ing out:  
 
Initial interview (specify approximate duration): 10 minutes.  
 
Health education sessions: Nil 
 
Clinical examination (Specify details and purpose): Nil 
 
Data collected will be stored for a period of five years. We  will not use the data as 
part of another study. 
 
Blood sample collection: Specify quantity of blood being drawn: 4 ml.  
 
No. of times it will be collected: 2 
 
Whether blood sample collection is part of routine procedure or for research (study) 
purpose:   
Research purpose 
Specify purpose, discomfort likely to be felt and side effects, if any: Pain while 
pricking 
 
Whether blood sample collected will be stored after study period: No, it will be de-
stroyed 
 
Whether blood sample collected will be sold:  No  
 
Whether blood sample collected will be shared with persons from another institution:
 No 
 
Medication given, if any, duration, side effects, purpose, benefits: Nil 
 
Benefits from this study: This study will be helpful in predicting optimal acenocou-
marol dose requirements.  This study identifies patients at increased risk of supra-
therapeutic INR (International Normalized Ratio) values and cerebrovascular bleed-
ing events. This allows personalization of dosing and to prevent cerebrovascular 
bleeding events. 
Risks involved by participating in this study: No risks 
 
How the results will be used:  Clinical Meeting at PSG Hospitals 
                                                   Dr.MGR Medical University dissertation 
 
If you are uncomfortable in answering any of our questions during the course of the 
interview / biological sample collection, you have the right to withdraw from the 
interview / study at anytime. You have the freedom to withdraw from the study at 
any point of time. Kindly be assured that your refusal to participate or withdrawal at 
any stage, if you so decide, will not result in any form of compromise or discrimina-
tion in the services offered nor would it attract any penalty. You will continue to have 
access to the regular services offered to a patient. You will NOT be paid any remune-
ration for the time you spend with us for this interview / study. The information pro-
vided by you will be kept in strict confidence. Under no circumstances shall we re-
veal the identity of the respondent or their families to anyone. The information that 
we collect shall be used for approved research purposes only. You will be informed 
about any significant new findings - including adverse events, if any, – whether di-
rectly related to you or to other participants of this study, developed during the course 
of this research which may relate to your willingness to continue participation. 
 
 
 
 
 
 
Consent: The above information regarding the study, has been read by me/ read to 
me, and has been explained to me by the investigator/s. Having understood the same, 
I hereby give my consent to them to interview me. I am affixing my signature / left 
thumb impression to indicate my consent and willingness to participate in this study 
(i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
 
 
 
Signature of the Interviewer with date: 
                                                            Witness: 
 
 
Contact number of PI: 9566611668 
Contact number of Ethics Committee Office:  0422 2570170 Extn: 5818 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MEDICATION HISTORY REVIEW FORM 
 
OP Number :                                                                               Date           : 
Patient Name :                                                                               Ward/Dept: 
Age  :                                                                                Sex       : M / F 
Height (cm) :                                                                                Weight (kg): 
 
SOCIAL HISTORY                              
Occupation             : _____________________________________________ 
Marital Status : _______________________________________________ 
Family History : _______________________________________________ 
 Social Habits 
Diet       Veg             Non -Veg 
Coffee/Tea       Yes                   No 
Smoking       Yes                   No  
Tobacco       Yes                   No 
Alcohol       Yes                   No 
 
      
FOR PATIENTS ON ACENOCOUMAROL 
           HISTORY              YES                         NO 
1)No of months  or years after surgery 
 
  
2)No of months or years on acenocoumarol 
 
  
3) Any history of bleeding? (ADR) 
 
  
4)History of bleeding  tendencies or blood 
disorder 
 
  
 
IMMUNIZATION HISTORY (If 
any):_____________________________________________ 
ALLERGIES :( If any) ___________________________________________ 
PAST MEDICAL HISTORY : ________________________________________ 
PAST MEDICATION HISTORY : ________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
COMPLIANCE   :                Yes          No 
PREVIOUS LAB DATA (If 
any):___________________________________________________ 
 
OVER THE COUNTER MEDICATIONS (If 
any):___________________________________ 
__________________________________________________________________________ 
 
PRESENT LAB DATA : ________________________________________________ 
         
                                                _________________________________________________ 
       
                                                _________________________________________________ 
   
 DIAGNOSIS   : 
_________________________________________________ 
 
                                                                                                                                                                                        
TREATMENT   
S.No Drugs Dose/Dosage Directions Indication 
     
     
     
     
     
     
     
  
   
Data collected by         
Name :          
Sign :          
